Original Publication Date: 1 October, 2015
Publication / Source: Immunotherapy
Authors: Mikio Kajihara, Kazuki Takakura, Toshifumi Ohkusa & Shigeo Koido
Dendritic cells (DCs) are potent antigen-presenting cells that can be used in cancer vaccines. Thus, various strategies have been developed to deliver tumor-associated antigens via DCs. One strategy includes administering DC–tumor fusion cells (DC–tumor FCs) to induce antitumor immune responses in cancer patients. However, clinical trials using this strategy have fallen short of expectations. Several factors might limit the efficacy of these anticancer vaccines.